高血圧治療に何か抜けていませんか?

出版社： 先端医学社
著者：
発行日： 2016-10-01
分野： 臨床医学：内科  >  血管
ISBN： 9784865502138
電子書籍版： 2016-10-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,750 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,650 円(税込)

購入する

商品紹介

日常臨床で見落としがちな、服薬アドヒアランスの向上を呼びかける探究の書。高血圧治療の臨床では、ガイドライン通りに薬剤を処方しているのにもかかわらず、血圧がなかなか安定しない難治性高血圧の患者に時折遭遇する。そのような場合、医療者は「その処方薬が本当に服用されているのか？」を見直す必要がある。本書では、高血圧治療の落とし穴である服薬アドヒアランスの向上について、やさしい語り口で探究する。明日からの診療が少し変わる、医療チームへの問いかけの一冊。

目次

  • 高血圧治療に何か抜けていませんか？

    ―目次―

    1 服薬アドヒアランス不良によって生じる諸問題
    2 高血圧患者さんの服薬アドヒアランス向上について考える
    3 服薬アドヒアランス向上のための5つのポイン
    4 服薬指導における各スタッフの役割
    5 患者さんに応じた多様なアプローチを考える

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

文献

P.113 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 編:高血圧治療ガイドライン2014(JSH2014). ライフサイエンス出版, 東京, 2014
 
2) Law MR, Morris JK, Wald NJ:Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 ran-domised trials in the context of expectations from prospective epide-miological studies. BMJ 338:b1665, 2009
 
3) Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM et al:Treatment of hypertension in patients 80 years and older:the lower the better? A meta-analysis of randomized controlled trials. J Hypertens 28:1366-1372, 2010
 
4) Asayama K, Ohkubo T, Yoshida S et al:Japan Arteriosclerosis Longi-tudinal Study(JALS) group. Stroke risk and antihypertensive drug treatment in the general population:the Japan arteriosclerosis longi-tudinal study. J Hypertens 27:357-364, 2009
 
5) Calhoun DA, Jones D, Textor S et al:Resistant hypertension:diagno-sis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Coun-cil for High Blood Pressure Research. Hypertension 51:1403-1419, 2008
 
6) Laufs U, Rettig-Ewen V, Bohm M:Strategies to improve drug adher-ence. Eur Heart J 32:264-268, 2011
 
7) Ho PM, Bryson CL, Rumsfeld JS:Medication adherence:its impor-tance in cardiovascular outcomes. Circulation 119:3028-3035, 2009
 
8) World Health Organization:Adherence to long-term therapies Evidence for action. 2003
 
9) Horne R, Weinman J, Barber N et al:Concordance, adherence and compliance in medicine taking. Report for the national co-ordinating centre for NHS service delivery and organization R & D (NCCSDO). 2005
 
10) Ruzicka M, Hiremath S:Can drug work in patients who do not take them? The problem of non-adherence in resistant hypertension. Curr Hypertens Rep 17:579, 2015
PubMed
11) Brown MT, Bussell JK:Medication adherence:WHO Cares? Mayo Clin Proc 86:304-314, 2011
PubMed
12) Conn VS, Ruppar TM, Chase JAD et al:Interventions to improve medi-cation adherence in hypertensive patients:systematic review and meta-analysis. Curr Hypertens Rep 17:94, 2015
 
13) Flack JM, Novikov SV, Ferrario CM:Benefits of adherence to antihypertensive drug therapy. Eur Heart J 17:16-20, 1997
 
14) Sokol MC, McGuigan KA, Verbrugge RR et al:Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43:521-530, 2005
PubMed
15) Lucher TF, Vetter H, Siegenthaler W et al:Compliance in hyperten-sion:facts and concepts. Hypertension 3:S3-S9, 1985
 
16) Morisky DE, Levine DM, Green LW et al:Five year blood pressure con-trol and mortality following health education for hypertensive patients. Am J Public Health 73:153-162, 1963
 
17) Kim S, Shin DW, Yun JM et al:Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension 67:506-512, 2016
 
18) Ahluwalia SC, Gross CP, Chaudhry SI et al:Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med 26:1145-1151, 2011
PubMed
19) Chowdhury R, Khan H, Heydon E et al:Adherence to cardiovascular therapy:a meta-analysis of prevalence and clinical consequences. Eur Heart J 34:2940-2948, 2013
PubMed
20) Granger BB, Swedberg K, Ekman I et al:Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM pro-gramme:double-blind, randomised, controlled clinical trial. Lancet 366:2005-2011, 2005
 
21) Gehi AK, Ali S, Na B et al:Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease:the heart and soul study. Arch Intern Med 167:1798-1803, 2007
PubMed
22) Dormuth CR, Patrick AR, Shrank WH et al:Statin adherence and risk of accidents:a cautionary tale. Circulation 119:2051-2057, 2009
PubMed
23) 日本薬剤師会:後期高齢者の服薬における問題と薬剤師の在宅患者訪問薬剤管理指導ならびに居宅療養管理指導の効果に関する調査研究報告書. 2008
 
24) Burkhart PV, Sabate E:Adherence to long-term therapies:evidence for action. J Nurs Scholarsh 35:207, 2003
 
25) Kolandaivelu K, Leiden BB, O'Gara PT et al:Non-adherence to cardio-vascular medications. Eur Heart J 35:3267-3276, 2014
 
26) Glader EL, Sjolande M Eriksson M:Persistent use of secondary pre-ventive drugs declines rapidly during the first 2 years after stroke. Stroke 41:397-401, 2010
 
27) Benner JS, Chapman RH, Petrilla AA et al:Association between pre-scription burden and medication adherence in patients initiating anti-hypertensive and lipid-lowering therapy. Am J Health Syst Pharm 66:1471-1477, 2009
 
28) Osterberg L, Blaschke T:Adherence to medication. N Engl J Med 353:487-497, 2005
PubMed
29) Krueger K, Botermann L, Schorr SO et al:Age-related medication adherence in patients with chronic heart failure:A systematic litera-ture review. Int J Cardiol 184:728-735, 2015
 
30) Levy D, Larson MG, Vasan RS et al:The progression from hypertension to congestive heart failure. JAMA 275:1557-1562, 1996
PubMed
31) Kostis JB, Davis BR, Cutler J et al:Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278:212-216, 1997
 
32) Pladevall M, Brotons C, Gabriel R et al:Writing Committee on behalf of the COM99 Study Group. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adher-ence and blood pressure control among patients at high cardiovascu-lar risk(the COM99 study). Circulation 122:1183-1191, 2010
 
33) Johansson JK, Niiranen TJ, Puukka PJ et al:Prognostic value of the variability in home-measured blood pressure and heart rate:the Finn-Home Study. Hypertension 59:212-218, 2012
PubMed
34) Kikuya M, Ohkubo T, Metoki H et al:Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis:the Ohasama study. Hypertension 52:1045-1050, 2008
PubMed
35) Parati G, Ochoa JE, Lombardi C et al:Assessment and management of blood-pressure variability. Nat Rev Cardiol 10:143-155, 2013
PubMed
36) Ghali JK, Kadakia S, Cooper R et al:Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 148:2013-2016, 1988
PubMed
37) Morisky DE, Green LW, Levine DM:Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74, 1986
PubMed
38) Morisky DE, Ang A, Krousel-Wood M et al:Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hyper-tens 10:348-354, 2008
 
39) 平塚祥子, 熊野宏昭, 片山潤ほか:服薬コンプライアンス尺度-服薬コンプライアンス尺度の作成-. 薬学雑誌 120:224-229, 2000
 
40) 上野治香, 山崎喜比古, 石川ひろの ほか:日本の慢性疾患患者を対象とした服薬アドヒアランス尺度の信頼性及び妥当性の検討. 日本健康教育学会誌 22:13-29, 2014
 
41) Muntner P, Yun H, Sharma P et al:Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event. Am J Cardiol 114:826-831, 2014
PubMed
42) Hall JE:Integration and regulation of cardiovascular function. Am J Physiol 277:S174-S 186, 1999
 
43) Ohkubo T, Asayama K, Kikuya M et al:How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 22:1099-1104, 2004
PubMed
44) Niiranen TJ, Hanninen MR, Johansson J et al:Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure:the Finn-Home study. Hypertension 55:1346-1351, 2010
PubMed
45) Aronow WS, Fleg JL, Pepine CJ et al:ACCF/AHA 2011 expert consen-sus document on hypertension in the elderly:a report of the American College of Cardiology Foundation Task Force on Clinical Expert Con-sensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Soci-ety for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 57:2037-2114, 2011
 
46) 健康日本21計画策定検討報告書. 2000
 
47) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:a meta-analysis. Lancet 358:1305-1315, 2001
PubMed
48) Wu JY, Leung WY, Chang S et al:Effectiveness of telephone counsel-ling by a pharmacist in reducing mortality in patients receiving poly-pharmacy:randomised controlled trial. BMJ 333:522, 2006
 
49) Dusing R Handrock R, Klebs S et al:Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan:the randomized, open-label, parallel group study VALIDATE. J Hypertens 27:894-901, 2009
 
50) Claxton AJ, Cramer J, Pierce C:A systematic review of the associa-tions between dose regimens and medication compliance. Clin Ther 23:1296-1310, 2001
 
51) Kumagai N, Onishi K, Hoshino K et al:Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens 35:355-360, 2012
PubMed
52) Chapman RH, Benner JS, Petrilla AA et al:Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165:1147-1152, 2005
PubMed
53) Srivastava K, Arora A, Kataria A et al:Impact of reducing dosing fre-quency on adherence to oral therapies:a literature review and meta-analysis. Patient Preference Adherence 7:419-434, 2013
 
54) Bangalore S, Kamalakkannan G, Parkar S et al:Fixed-dose combina-tions improve medication compliance:a meta-analysis. Am J Med 120:713-719, 2007
 
55) Brenner BM, Cooper ME, de Zeeuw D et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
PubMed
56) Hasebe N, Kikuchi K:Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension:the NICE Combi(Nifedipine and Candesartan Combination)Study. J Hypertens 23:445-453, 2005
PubMed
57) Ogawa H, Kim-Mitsuyama S, Matsui K et al:Olmesartan and calcium antagonists randomized(OSCAR) Study Group. Angiotensin II recep-tor blocker-based therapy in Japanese elderly, high-risk, hyperten-sive patients. Am J Med 125:981-990, 2012
 
58) Drugs for the heart 3rd ed, eds by Opie LH, Philadelphia, WB Saunders, 1991, pp.42-73
 
59) White WB, Viadero JJ, Lane TJ et al:Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 39:43-48, 1986
PubMed
60) Gustafsson D:Microvascular mechanisms involved in calcium antago-nist edema formation. J Cardiovasc Pharmacol 10(Suppl. 1):S121-S131, 1987
 
61) Messerli FH, Oparil S, Feng Z:Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor(benazepril) with calcium antagonist(either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hyper-tension. Am J Cardiol 86:1182-1187, 2000
PubMed
62) Gradman AH, Acevedo C:Evolving strategies for the use of combina-tion therapy in hypertension. Curr Hypertens Rep 4:343-349, 2002
 
63) Yusuf S, Islam S, Chow CK et al:Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries(the PURE Study):a prospective epidemiological survey. Lancet 378:1231-1243, 2011
PubMed
64) Thom S, Poulter N, Field J et al:Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD:the UMPIRE randomized clinical trial. JAMA 310:918-929, 2013
PubMed
65) Castellano JM, Sanz G, Penalvo JL et al:A polypill strategy to improve adherence. Results from the FOCUS project. J Am Coll Cardiol 64:2071-2082, 2014
PubMed
66) Intersalt Cooperative Research Group:Intersalt:an international study of electrolyte excretion and blood pressure. Results for 24 hour uri-nary sodium and potassium excretion. Lancet 297:319-328, 1988
 
67) 厚生労働省:平成20年国民健康栄養調査報告. 2008
 

書評

最近チェックした商品履歴

Loading...